Stoke Therapeutics, Inc. (STOK) FY2026 YTD Q2 P&L / Income Statement

Stoke Therapeutics, Inc. (STOK) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenue

15,554,000 US dollars

Total operating expenses

134,401,000 US dollars

(Loss) income from operations

negative 118,847,000 US dollars

Total other income (expense)

7,226,000 US dollars

(Loss) income before income taxes

negative 111,621,000 US dollars

Provision for income taxes

0 US dollars

Net (loss) income

negative 111,621,000 US dollars

Acadia Agreement

5,000,000 US dollars

Biogen License Agreement

10,563,000 US dollars

Total operating expenses

134,401,000 US dollars

Revenue before reconciliation (calculated)

15,563,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.

Components above reported revenue (calculated)

negative 9,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.